Premium
GLP ‐1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents
Author(s) -
Trujillo Jennifer M.,
Nuffer Wesley
Publication year - 2014
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.1507
Subject(s) - medicine , glycemic , dulaglutide , adverse effect , type 2 diabetes , hypoglycemia , liraglutide , exenatide , glucagon like peptide 1 receptor , insulin , type 2 diabetes mellitus , postprandial , diabetes mellitus , weight loss , pharmacology , endocrinology , obesity , receptor , agonist
More than 26 million people in the United States have type 2 diabetes mellitus (T2D). Many treatment options exist, but achieving long‐term glycemic control in patients with T2D remains challenging. The glucagon‐like peptide‐1 receptor agonists ( GLP ‐1 RA s) offer a treatment option that improves glycemic control and reduces weight, with a low risk of hypoglycemia. They have emerged as attractive options for the treatment of T2D, and significant advances and developments continue to be published regarding these agents. To identify relevant literature on emerging issues related to GLP ‐1 RA s, a search of the MEDLINE database was performed. Studies published in English evaluating the safety and efficacy of GLP ‐1 RA s were analyzed. Because of their advantages and unique mechanism of action, GLP ‐1 RA s are currently being studied in new clinical areas, including in combination with basal insulin, as adjunctive therapy in type 1 diabetes, and for weight loss. In addition, there are several emerging agents in development. Lixisenatide is a once‐daily GLP ‐1 RA that targets postprandial glucose and may be most useful when added to basal insulin as an alternative to rapid‐acting insulin. Albiglutide and dulaglutide are once‐weekly GLP ‐1 RA s that may offer more convenient dosing. The most common adverse effects of all GLP ‐1 RA agents are gastrointestinal (e.g., nausea, diarrhea, and vomiting), but the rates of occurrence vary among agents. Due to the differences in pharmacokinetics, efficacy, rates of adverse effects, and administration requirements within the GLP ‐1 RA class, each agent should be evaluated independently. The future of GLP ‐1 RA s offers broader treatment options for T2D as well as potential in other treatment areas.